Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immuneering Corp Cl A (NQ: IMRX )

2.390 -0.060 (-2.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 700,318
Open 2.470
Bid (Size) 2.430 (1)
Ask (Size) 2.510 (2)
Prev. Close 2.450
Today's Range 2.301 - 2.550
52wk Range 1.000 - 8.890
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
Immuneering reported promising initial response data from its Phase 2a trial for IMM-1-104 combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a 40% response rate... 
Via Benzinga

Performance

YTD
-67.35%
-67.35%
1 Month
+106.03%
+106.03%
3 Month
+113.39%
+113.39%
6 Month
+12.74%
+12.74%
1 Year
-66.15%
-66.15%

More News

Read More
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
From Immuneering Corporation
Via GlobeNewswire
Why is Immuneering (IMRX) Stock Up 24% Today?
Via InvestorPlace
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
Via Benzinga
Why Carvana Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Immuneering to Present at the Jefferies Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024
Via InvestorPlace
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Immuneering Recognizes Melanoma Awareness Month
From Immuneering Corporation
Via GlobeNewswire
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
From Immuneering Corporation
Via GlobeNewswire
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
3 Stocks Insiders Are Buying That Analysts Love
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data
Via Benzinga
Dow Falls Over 200 Points; Adobe Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.